Atopic Dermatitis

Together with earlier trials presented at EADV, these findings support OX40 receptor inhibition as a promising therapeutic approach for AD.

At EADV 2025, she showcased how OX40 and JAK inhibition offer complementary approaches to long-term disease control.

Nicole Harter, MD, explores ruxolitinib 1.5% cream for pediatric atopic dermatitis, offering a novel, effective treatment option for children aged 2 to 11.

Ruxolitinib cream has become the first topical JAK inhibitor available for pediatric atopic dermatitis (AD) in the US.

Major unmet needs in pediatric AD include rapid itch relief, access, affordability, and better options for sensitive skin.

LEO Pharma unveils promising phase 2b trial results for temtokibart, showcasing significant improvements in atopic dermatitis at EADV Congress 2025.

Presented at EADV Congress 2025, galvokimig showed promising early results in treating moderate to severe atopic dermatitis, targeting multiple inflammatory pathways for effective relief.

Data presented at EADV 2025 on the ROCKET-SHUTTLE trial demonstrate that rocatinlimab, a T-cell rebalancing therapy, significantly improves the signs and symptoms of moderate to severe AD in adults when used with topical therapies.

A new study at EADV 2025 links atopic dermatitis to increased suicidal ideation, highlighting the condition's severe psychological impact.

New guidelines redefine short-term corticosteroid use in patients with AD, urging safer treatment transitions to advanced therapies for better outcomes.

Experts discuss innovative topical therapies for pediatric AD, emphasizing individualized treatment and the importance of managing itch and sleep quality.

Cigna’s removal of restrictions on home phototherapy, following a similar decision by Elevance Health, expands access to more than 66 million Americans.

Utilization management programs for atopic dermatitis may hinder patient care, causing treatment delays and increased costs despite advances in biologic therapies.

Upadacitinib maintained high EASI and itch response rates through nearly 3 years of treatment.

Explore innovative treatments for seborrheic dermatitis, including roflumilast foam, and learn about effective patient-centered care strategies.

Amlitelimab shows promising phase 3 results in treating atopic dermatitis, achieving significant skin clearance and potential for infrequent dosing.

Phase 3 topline results reveal rocatinlimab's promising safety and efficacy for moderate to severe AD, targeting the OX40 receptor.

The study found that 59% of patients achieved IGA treatment success, surpassing other topical therapies.

Cases of dermatitis in workers and consumers alike show how allergen exposure transcends occupational boundaries.

Renata Block, DMSc, MMS, PA-C, and Isabelle Thibau, MPH, of the National Eczema Association discuss how the EczemaWise app integrates patient-reported outcomes, validated tools, and real-world data to improve collaboration between patients and clinicians in managing eczema.

Case reports showed encouraging outcomes in eczema, but the company is pursuing deeper validation.

Clinicians explore innovative strategies for managing atopic dermatitis, emphasizing personalized care and the use of non-steroidal treatments for improved patient outcomes.

April Martinez-Dulay, MSN, APRN, FNP-BC, shares insights on diagnosing and treating types of dermatitis at DERM 2025, emphasizing innovative approaches and patient care strategies.

Walter Liszewski, MD, shares expert strategies for managing body surface area limitations in AD treatment using non-steroidal topicals, and explored key unmet needs in the current therapeutic landscape.

James Song, MD, FAAD, reveals insights on abrocitinib's safety in atopic dermatitis, highlighting lower conjunctivitis rates compared to dupilumab at DERM 2025.